REG - Oncimmune Hldgs PLC - PDMR Dealing

Oncimmune HoldingsAnnouncement

21/09/2022 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220921:nRSU1888Aa&default-theme=true

RNS Number : 1888A  Oncimmune Holdings PLC  21 September 2022

 

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

PDMR Dealing

 

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, has been notified that Dr Adam Mark Hill, PDMR and Chief Executive
Officer, today purchased 8,005 ordinary shares of £0.01 each in the Company
("Ordinary Shares") for £0.624599 per share.

 

Following this transaction, Dr Hill has a total interest in the Company of
73,872 Ordinary Shares, representing approximately 0.11 per cent of the
Company's issued share capital of 69,475,480.

 

In addition, Dr Hill holds options over a total of 3,490,862 Ordinary Shares,
representing approximately 5.02 per cent of the Company's issued share
capital.

 

This announcement, including the notification below, is made in accordance
with the requirements of Article 19 of the UK Market Abuse Regulation.

 

Notification and public disclosure of transactions by person discharging
managerial responsibilities and persons closely associated with them:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Adam Mark Hill

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Oncimmune Holdings plc

 b)   LEI                                                          213800HCYIWT6YPI1I02

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          ISIN: GB00BYQ94H38

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     £0.624599         8,005

 d)   Aggregated information                                       N/A - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      21 September 2022

 f)   Place of the transaction                                     London Stock Exchange, AIMX

 

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Investor Relations:

John Goold

IR@oncimmune.com

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organizations to optimize drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programs, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAAORUSUKUAR